| Active ingredient (INN) | Nivolumab |
|---|---|
| Brand names | Opdivo |
| Therapeutic category | Auto-created by Agenzia Italiana del Farmaco — Carenze scraper |
| Controlled substance | No |
| Marketing-authorisation holders | Bristol-Myers Squibb Australia Pty Ltd, Bristol-Myers Squibb Pharma EEIG |
| Registrations on file | 5 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| OPDIVO nivolumab | 240 mg | — | 🇦🇺 AU | Bristol-Myers Squibb Australia Pty Ltd | Active |
| OPDUALAG nivolumab | 240mg | — | 🇦🇺 AU | Bristol-Myers Squibb Australia Pty Ltd | Active |
| OPDIVO nivolumab | 40 mg | — | 🇦🇺 AU | Bristol-Myers Squibb Australia Pty Ltd | Active |
| OPDIVO nivolumab | 100 mg | — | 🇦🇺 AU | Bristol-Myers Squibb Australia Pty Ltd | Active |
| Nivolumab BMS | — | — | 🌐 EU | Bristol-Myers Squibb Pharma EEIG | Withdrawn |